Larn Hwang

Oncotelic, Inc. develops a therapeutic platform for cancer treatments. It conducts registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The company was founded by Vuong Trieu and Chulho Park and is headquartered in Agoura Hills, CA.

Autotelic, Inc. manufactures therapeutics drugs. Its Therapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. The company was founded in 2013 and is headquartered in Costa Mesa, CA.

Part of Cambridge Equities LP, IgDraSol, Inc. is a company that manufactures cancer therapeutics. The company is based in Fountain Valley, CA. The company was founded by Larn Hwang, Vuong Trieu. IgDraSol was acquired by NantPharma LLC from Sorrento Therapeutics, Inc. on May 15, 2015 for $1,290 million.

Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.